Abstract
Collaborations between Emerging and Leading In-vitro Cancer Diagnostics Companies Vital for
Greater Market Penetration
With cancer-related deaths in Europe touching one million, there has been a substantial rise in
the consumption of resources for diagnosis, treatment and care. Throughout Europe, the five-year
survival rate of cancer patients is a mere 30 per cent to 60 per cent. However, in recent times,
there has been a reduction in the mortality rate by 10 per cent, which is a gain of 92,000 lives. In
this scenario, the in-vitro cancer diagnostics industry is expected to play a vital role in tackling
this disease, with encouragement from the collaboration between emerging diagnostic companies and
leading participants. Collaborations help the smaller participants with invaluable intellectual
property rights, market their tests better.
This Frost & Sullivan research service provides an overview of and outlook for the European
in-vitro cancer diagnostics market. The research provides detailed revenue forecasts by end user to
help design marketing strategies and maximise growth. The study looks at the vast potential the
market holds on account of the range of potential therapeutic approaches available to treat cancer.
This enables companies to align their positioning strategies to benefit from the changing markets
and obtain maximum return on investments.
Ageing Population Increase Incidence of Cancer, Driving Demand for In-vitro Diagnostics
The European population is slowly ageing, with 17 per cent of the population in almost all the
countries being aged 65 years and above. This swelling population segment coupled with the largely
unhealthy lifestyle of the Europeans is likely to double the current number of cancer-related cases
by 2020, creating robust demand for in-vitro diagnostics. Moreover, the varying survival rates in
different European nations strongly indicate that market participants are likely to find immense
opportunities in the countries with low cure rates.
"The in-vitro cancer diagnostics market needs to meet the increasing demand for accurate
diagnosis, as the concept of personalised medicine is consistently evolving," notes the analyst
of this research. "With more numbers of personalised drugs entering the market, it has become
important to determine the success rate of a particular treatment on a patient, which, in turn,
stresses the need for in-vitro diagnostics."
Newer Drugs and Treatment Methods to Drive the Market
The $523 million in-vitro cancer diagnostics market had grown at 7.0 per cent in 2004 and is
projected to expand further to reach $885 million in 2011. This substantial growth is likely to be
primarily fuelled by the introduction of more effective drugs and treatment methods, which has,
consequently, necessitated greater number of tests for monitoring and therapy selection.
"Governments have also realised the advantages of early screening and detection in cancer
diagnostics and have been bringing newer diseases under the purview of national screening programmes,"
states the analyst. "Due to various government-funded research activities in the field of
in-vitro diagnostics, a lot of information on innovative cancer markers has been obtained, building
up a strong pipeline of newer tests."
View Cart
